194 related articles for article (PubMed ID: 14698036)
1. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
[TBL] [Abstract][Full Text] [Related]
2. Fenproporex N-dealkylation to amphetamine--enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats.
Kraemer T; Pflugmann T; Bossmann M; Kneller NM; Peters FT; Paul LD; Springer D; Staack RF; Maurer HH
Biochem Pharmacol; 2004 Sep; 68(5):947-57. PubMed ID: 15294457
[TBL] [Abstract][Full Text] [Related]
3. In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step.
Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
Xenobiotica; 2004 Feb; 34(2):179-92. PubMed ID: 14985146
[TBL] [Abstract][Full Text] [Related]
4. New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine.
Staack RF; Fritschi G; Maurer HH
J Mass Spectrom; 2003 Sep; 38(9):971-81. PubMed ID: 14505325
[TBL] [Abstract][Full Text] [Related]
5. Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.
Springer D; Paul LD; Staack RF; Kraemer T; Maurer HH
Drug Metab Dispos; 2003 Aug; 31(8):979-82. PubMed ID: 12867484
[TBL] [Abstract][Full Text] [Related]
6. Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine.
Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
Drug Metab Dispos; 2004 Apr; 32(4):379-81. PubMed ID: 15039289
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
8. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
Ewald AH; Maurer HH
Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
[TBL] [Abstract][Full Text] [Related]
9. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes.
Yoshii K; Kobayashi K; Tsumuji M; Tani M; Shimada N; Chiba K
Life Sci; 2000; 67(2):175-84. PubMed ID: 10901285
[TBL] [Abstract][Full Text] [Related]
10. Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS).
Steuer AE; Williner E; Staeheli SN; Kraemer T
Drug Test Anal; 2017 Jul; 9(7):1085-1092. PubMed ID: 27736030
[TBL] [Abstract][Full Text] [Related]
11. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression.
Schulz-Utermoehl T; Bennett AJ; Ellis SW; Tucker GT; Boobis AR; Edwards RJ
Pharmacogenetics; 1999 Jun; 9(3):357-66. PubMed ID: 10471068
[TBL] [Abstract][Full Text] [Related]
12. Cyp2D6 catalyzes 5-hydroxylation of 1-(2-pyrimidinyl)-piperazine, an active metabolite of several psychoactive drugs, in human liver microsomes.
Raghavan N; Zhang D; Zhu M; Zeng J; Christopher L
Drug Metab Dispos; 2005 Feb; 33(2):203-8. PubMed ID: 15507542
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
Hutchinson MR; Menelaou A; Foster DJ; Coller JK; Somogyi AA
Br J Clin Pharmacol; 2004 Mar; 57(3):287-97. PubMed ID: 14998425
[TBL] [Abstract][Full Text] [Related]
15. Human CYP2D6 and metabolism of m-chlorophenylpiperazine.
Rotzinger S; Fang J; Coutts RT; Baker GB
Biol Psychiatry; 1998 Dec; 44(11):1185-91. PubMed ID: 9836023
[TBL] [Abstract][Full Text] [Related]
16. Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone.
Peters FT; Meyer MR; Theobald DS; Maurer HH
Drug Metab Dispos; 2008 Jan; 36(1):163-8. PubMed ID: 17962373
[TBL] [Abstract][Full Text] [Related]
17. New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine.
Meyer MR; Vollmar C; Schwaninger AE; Wolf E; Maurer HH
J Mass Spectrom; 2012 Feb; 47(2):253-62. PubMed ID: 22359337
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 using different in vitro systems.
Baranczewski P; Edlund PO; Postlind H
J Pharm Biomed Anal; 2006 Mar; 40(5):1121-30. PubMed ID: 16307862
[TBL] [Abstract][Full Text] [Related]
19. Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.
Natsui K; Mizuno Y; Tani N; Yabuki M; Komuro S
Eur J Drug Metab Pharmacokinet; 2007; 32(3):131-7. PubMed ID: 18062405
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]